IMNM

Immunome Inc

21.49

Jul 01 • 04:00PM ET +0.30 (1.42%)

Healthcare Biotechnology USA Mid NASD

Peers: TNGX CGON KYMR NUVL INCY RYTM APGE KRYS AXSM BMRN

| Held by: VTI XBI IWM VXF IWO VTWO SCHA VHT CANC FYC

Index	RUT
Market Cap	2.43B
Enterprise Value	1.85B
Income	-224.59M
Sales	4.01M
Book/sh	5.20
Cash/sh	5.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	177
IPO	Oct 02, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	606.92
P/B	4.13
P/C	4.18
P/FCF	-
EV/EBITDA	-
EV/Sales	462.53
Quick Ratio	21.68
Current Ratio	21.68
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.38
EPS next Y	-2.16
EPS next Q	-0.51
EPS this Y	11.83%
EPS next Y	-0.86%
EPS next 5Y	22.81%
EPS past 3/5Y	7.72% -7.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	25.39%
Sales Y/Y TTM	-63.29%
EPS Q/Q	9.25%
Sales Q/Q	-100.00%
Earnings	May 12 AMC
EPS/Sales Surpr.	13.70% -100.00%

Insider Own	9.31%
Insider Trans	-2.06%
Inst Own	104.03%
Inst Trans	5.66%
ROA	-46.67%
ROE	-50.14%
ROIC	-37.91%
Gross Margin	25.73%
Oper. Margin	-5698.83%
Profit Margin	-5593.85%
SMA20	11.76%
SMA50	1.95%
SMA200	8.75%
Trades

Shs Outstand	113.17M
Shs Float	102.70M
Short Float	17.67%
Short Ratio	13.84
Short Interest	18.15M
52W High	27.65 -22.28%
52W Low	7.96 169.97%
Volatility	6.28% 4.86%
ATR (14)	1.02
RSI (14)	61.98
Beta	2.07
Rel Volume	1.55
Avg Volume	1.31M
Volume	2,030,056

Perf Week	8.81%
Perf Month	3.42%
Perf Quarter	-1.74%
Perf Half Y	-0.51%
Perf YTD	0.05%
Perf Year	153.87%
Perf 3Y	171.68%
Perf 5Y	25.67%
Perf 10Y	-
Recom	1.07
Target Price	35.77
Prev Close	21.19
Price	21.49
Change	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-26	Initiated	Barclays	Overweight	$36
Feb-12-26	Initiated	H.C. Wainwright	Buy	$40
Dec-01-25	Initiated	Truist	Buy	$36
Sep-22-25	Initiated	Goldman	Buy	$26
Sep-05-25	Initiated	Craig Hallum	Buy	$26
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Show Previous Ratings

Jun-11-26 07:30AM	Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors (Business Wire)
Jun-04-26 04:02PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.59%
May-30-26 08:00AM	Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting (Business Wire)
May-28-26 11:26AM	Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
May-27-26 08:00AM	Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
04:02PM	Loading…
May-12-26 04:02PM	Immunome Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-29-26 07:30AM	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
Apr-21-26 10:30AM	Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting (Business Wire)
Apr-02-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.97%
Mar-03-26 04:02PM	Immunome Reports Full Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-02-26 02:57AM	Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development (Insider Monkey)
Feb-23-26 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 11:03PM	Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses (MarketBeat)
09:44AM	Loading…
Feb-12-26 09:44AM	Shopify upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
Feb-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.13%
Feb-04-26 08:00AM	Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
Jan-15-26 11:35AM	Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? (Insider Monkey) +10.07%
Jan-08-26 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:45AM	Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" (Insider Monkey)
Jan-06-26 08:00AM	Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:05PM	Lightning Round: Nokia is up against a lot of tough companies, says Jim Cramer (CNBC TV) -5.33%
Dec-16-25 08:16PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire) -15.76%
07:26AM	Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win (Clinical Trials Arena)
Dec-15-25 06:03PM	Why Immunome Stock Surged Today (Motley Fool) +15.69%
04:36PM	Stocks Fall Ahead of US November Payroll Report (Barchart)
04:34PM	Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA (Investor's Business Daily)
04:01PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
12:53PM	Loading…
12:53PM	Stock Market Today: Russell 2000, Nasdaq Decline After Strong Start to Trading Week (TheStreet)
07:00AM	Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-14-25 04:00PM	Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Nov-06-25 04:05PM	Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.35%
Oct-31-25 11:51AM	Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference (Business Wire)
Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

ChairmanDr. Clay B. Siegall Ph.D.

Chief Financial OfficerMr. Max Rosett

Chief Medical OfficerDr. Robert J. Lechleider M.D.

Chief Technical OfficerDr. Philip Tsai

Chief Scientific OfficerDr. Jack Higgins Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ABHMC II, LLC	Shareholder	Jun 30 '26	Proposed Sale	21.04	100,000	2,104,000		Jun 30 05:20 PM
Arsenal Bridge Venture II-B, L	Shareholder	Jun 30 '26	Proposed Sale	21.04	1,050	22,092		Jun 30 05:20 PM
Lechleider Robert	Chief Medical Officer	Jun 25 '26	Option Exercise	8.73	55,000	480,150	70,805	Jun 29 04:52 PM
Lechleider Robert	Chief Medical Officer	Jun 25 '26	Sale	19.85	55,000	1,091,662	15,805	Jun 29 04:52 PM
Lechleider Robert	Officer	Jun 25 '26	Proposed Sale	19.73	55,000	1,085,150		Jun 25 09:47 AM
Rosett Max	Chief Financial Officer	Jun 15 '26	Option Exercise	1.05	60,000	63,000	114,037	Jun 17 05:26 PM
Rosett Max	Chief Financial Officer	Jun 15 '26	Sale	18.23	60,000	1,093,800	54,037	Jun 17 05:26 PM
Rosett Max	Officer	Jun 15 '26	Proposed Sale	18.63	60,000	1,117,800		Jun 15 02:36 PM
BIENAIME JEAN JACQUES	Director	Jun 05 '26	Buy	19.45	10,500	204,260	43,415	Jun 09 05:40 PM
BIENAIME JEAN JACQUES	Director	Jun 05 '26	Sale	19.41	10,500	203,820	32,915	Jun 09 05:40 PM
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	20.70	5,000	103,500	43,415	May 19 07:56 AM
Higgins Jack	Chief Scientific Officer	Apr 02 '26	Sale	21.64	9,438	204,238	22,000	Apr 03 07:48 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Option Exercise	1.22	71,561	87,053	119,037	Apr 03 07:46 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Sale	21.92	65,000	1,424,916	54,037	Apr 03 07:46 PM
Rosett Max	Officer	Apr 02 '26	Proposed Sale	72.67	65,000	4,723,550		Apr 02 11:46 AM
Higgins Jack	Officer	Apr 02 '26	Proposed Sale	21.64	9,438	204,238		Apr 02 11:32 AM
SIEGALL CLAY B	President and CEO	Mar 27 '26	Buy	19.67	25,450	500,602	690,704	Mar 31 07:11 AM
WAGENHEIM PHILIP	Director	Mar 20 '26	Sale	20.47	36,800	753,296	369,347	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 23 '26	Sale	20.65	28,200	582,330	341,147	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 20 '26	Proposed Sale	20.81	65,000	1,352,640		Mar 20 12:56 PM
BIENAIME JEAN JACQUES	Director	Mar 10 '26	Buy	22.12	1,000	22,120	37,415	Mar 12 06:05 AM
BIENAIME JEAN JACQUES	Director	Mar 11 '26	Buy	21.55	1,000	21,550	38,415	Mar 12 06:05 AM
SIEGALL CLAY B	President and CEO	Dec 30 '25	Buy	21.15	4,729	100,018	665,254	Dec 30 06:47 PM
Barchas Isaac	Director	Dec 22 '25	Sale	21.74	383,200	8,330,080	2,031,181	Dec 23 04:41 PM
SIEGALL CLAY B	President and CEO	Dec 19 '25	Buy	20.48	7,278	149,053	860,525	Dec 22 07:38 AM
Tsai Philip	Chief Technical Officer	Dec 19 '25	Buy	20.49	10,000	204,900	43,300	Dec 22 07:32 AM
SIEGALL CLAY B	President and CEO	Dec 18 '25	Buy	21.50	46,511	999,986	853,247	Dec 18 05:03 PM
Higgins Jack	Chief Scientific Officer	Sep 10 '25	Option Exercise	1.35	22,000	29,700	40,729	Sep 11 09:04 PM

BMRN Biomarin Pharmaceutical Inc daily Stock Chart

Peers: ALNY IONS ARWR ASND BBIO RARE INCY CRSP EXEL VRTX

| Held by: IJH VTI VB VBK VXF XBI MDY FBT IBB SPMD

Index	-
Market Cap	11.18B
Enterprise Value	10.40B
Income	268.74M
Sales	3.29B
Book/sh	32.14
Cash/sh	11.50
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3221
IPO	Jul 23, 1999

P/E	42.19
Forward P/E	8.83
PEG	0.14
P/S	3.40
P/B	1.80
P/C	5.03
P/FCF	14.57
EV/EBITDA	12.83
EV/Sales	3.16
Quick Ratio	4.20
Current Ratio	5.81
Debt/Eq	0.23
LT Debt/Eq	0.23
Option/Short	Yes / Yes

EPS (ttm)	1.37
EPS next Y	6.54
EPS next Q	0.95
EPS this Y	174.71%
EPS next Y	32.35%
EPS next 5Y	61.81%
EPS past 3/5Y	34.05% -16.79%
Sales past 3/5Y	16.55% 11.97%
EPS Y/Y TTM	-49.09%
Sales Y/Y TTM	12.53%
EPS Q/Q	-43.10%
Sales Q/Q	6.28%
Earnings	May 04 AMC
EPS/Sales Surpr.	9.81% 1.79%

Insider Own	1.61%
Insider Trans	-1.65%
Inst Own	100.31%
Inst Trans	1.24%
ROA	3.42%
ROE	4.48%
ROIC	3.52%
Gross Margin	76.28%
Oper. Margin	22.40%
Profit Margin	8.17%
SMA20	2.40%
SMA50	5.84%
SMA200	3.79%
Trades

Shs Outstand	193.27M
Shs Float	190.18M
Short Float	6.58%
Short Ratio	6.00
Short Interest	12.52M
52W High	66.28 -12.76%
52W Low	49.26 17.38%
Volatility	3.29% 2.79%
ATR (14)	1.69
RSI (14)	57.90
Beta	0.24
Rel Volume	0.71
Avg Volume	2.09M
Volume	1,484,980

Perf Week	0.85%
Perf Month	5.07%
Perf Quarter	2.35%
Perf Half Y	-3.70%
Perf YTD	-2.71%
Perf Year	2.90%
Perf 3Y	-33.29%
Perf 5Y	-31.09%
Perf 10Y	-28.95%
Recom	1.63
Target Price	87.76
Prev Close	57.22
Price	57.82
Change	1.05%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Initiated	Citigroup	Buy	$75
May-11-26	Resumed	Goldman	Neutral	$69
Apr-27-26	Resumed	Morgan Stanley	Overweight	$120
Jan-28-26	Resumed	Barclays	Overweight	$80
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy	$98
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$60
Nov-06-25	Downgrade	Stifel	Buy → Hold	$61
Sep-08-25	Initiated	H.C. Wainwright	Neutral	$60
Sep-03-25	Initiated	Raymond James	Outperform	$85
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform

Show Previous Ratings

Jun-16-26 09:05AM	BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 (PR Newswire)
Jun-02-26 01:30AM	Centene, Deckers and 14 Other 'Dividend Hopefuls' (Barrons.com)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com) +8.63%
May-20-26 04:20PM	BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia (PR Newswire) +7.77%
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
07:58AM	Loading…
07:58AM	BioMarin drug acquired in buyout misses goal in rare disease study (BioPharma Dive)
May-18-26 09:05AM	BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency (PR Newswire)
May-11-26 09:44AM	Dell downgraded, Uber upgraded: Wall Street's top analyst calls (The Fly)
May-04-26 08:22PM	BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary (Moby)
04:25PM	BioMarin: Q1 Earnings Snapshot (Associated Press)
04:05PM	BioMarin Reports First Quarter 2026 Financial and Operating Results (PR Newswire)
May-02-26 03:30PM	BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting (PR Newswire)
Apr-28-26 05:51AM	BioMarin acquires Amicus Therapeutics for $4.8bn (Pharmaceutical Technology)
Apr-27-26 09:51AM	Snap upgraded, Pinterest downgrade: Wall Street's top analyst calls (The Fly)
08:44AM	BioMarin Completes Acquisition of Amicus Therapeutics (PR Newswire)
07:30AM	Loading…
07:30AM	BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET (PR Newswire)
Apr-21-26 04:23PM	BioMarin Announces Board Leadership Transition (PR Newswire)
Mar-12-26 09:05AM	BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-10-26 02:49PM	BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz (Benzinga)
Mar-09-26 02:45PM	Do Options Traders Know Something About BMRN Stock We Don't? (Zacks)
Mar-07-26 02:48AM	BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab (MarketBeat)
Mar-04-26 06:00AM	BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients (Benzinga)
Mar-02-26 11:04PM	2 Reasons to Like BMRN (and 1 Not So Much) (StockStory)
07:22AM	Ascendis wins FDA approval of dwarfism drug (BioPharma Dive)
06:10AM	BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients (Benzinga)
Mar-01-26 04:27AM	Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 - Here's Why (Insider Monkey)
Feb-28-26 02:21AM	Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why (Insider Monkey)
Feb-27-26 08:00PM	U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) (PR Newswire)
Feb-26-26 12:36PM	BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo (Insider Monkey)
04:39AM	Boehringer drug approved in 44 days; BioMarin shelves Roctavian (BioPharma Dive)
04:51PM	Loading…
Feb-24-26 04:51PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
09:00AM	BioMarin to Participate in Four Upcoming Investor Conferences in March (PR Newswire)
08:30AM	BioMarin Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
12:02AM	BioMarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-23-26 08:00PM	Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics (Zacks)
07:25PM	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
06:18PM	BioMarin Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
05:08PM	BioMarin: Q4 Earnings Snapshot (Associated Press Finance)
04:50PM	BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates (StockStory)
04:05PM	BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results (PR Newswire)
11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
Feb-21-26 10:07PM	BioMarin Pharmaceutical Earnings: What To Look For From BMRN (StockStory)
Feb-19-26 09:15AM	Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics (Zacks)
Feb-17-26 09:00AM	BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET (PR Newswire)
Feb-16-26 02:11PM	What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
12:24PM	What Makes BioMarin (BMRN) so Attractive (Insider Monkey)
Feb-13-26 04:31PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Feb-12-26 04:05PM	BioMarin Announces Closing of Private Offering of Senior Notes (PR Newswire)
12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
08:30AM	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
Feb-08-26 03:49AM	What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? (Insider Monkey)
Feb-07-26 04:09AM	Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays (Insider Monkey)
Jan-31-26 05:04AM	Should You Buy BioMarin Pharmaceutical Before Feb. 18? (Motley Fool)
Jan-29-26 04:05PM	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
06:57AM	Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Jan-27-26 07:22AM	Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis (Insider Monkey)
Jan-26-26 07:45AM	BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-22-26 06:02AM	BioMarin vets form Mendra to modernize rare disease drug development (BioPharma Dive)
Jan-16-26 11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 10:08AM	Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical (Zacks)
08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-14-26 12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)
08:52AM	4 Value Stocks to Buy As Wall Street Weighs Trump Policies (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:40AM	Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? (Zacks)
05:46AM	BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference (MarketBeat)
Jan-12-26 04:05PM	BioMarin Appoints Arpit Dave Chief Digital and Information Officer (PR Newswire)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jan-08-26 04:05PM	BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA (PR Newswire)
08:30AM	Veeva and BioMarin Form Long-Term Strategic Partnership (PR Newswire)
Jan-05-26 04:26AM	10 Magnificent Stocks That Can Make You Richer in 2026 (Motley Fool)
Jan-01-26 06:29AM	H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver (Insider Monkey)
Dec-30-25 11:54AM	Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? (Insider Monkey)
Dec-29-25 09:30PM	Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio? (Benzinga)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 02:35PM	BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know (StockStory)
Dec-22-25 10:18PM	Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition (Insider Monkey)
09:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
Dec-20-25 08:13AM	BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +17.71%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
04:16PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today (StockStory)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:06AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

PresidentMr. Alexander Hardy

CFO & Executive VP of FinanceMr. Brian R. Mueller CPA

Executive VP & CTODr. C. Greg Guyer Ph.D.

Executive VP & Chief Commercial OfficerMs. Cristin Hubbard

Executive VP and Chief Research & Development OfficerDr. Gregory Friberg M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Friberg Gregory R	EVP, Chief R&D Officer	May 07 '26	Sale	53.85	3,281	176,682	51,818	May 11 05:01 PM
Friberg Gregory R	Officer	May 07 '26	Proposed Sale	53.85	3,281	176,682		May 07 01:17 PM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 11 '26	Sale	60.46	16,486	996,744	79,953	Mar 12 07:55 PM
Guyer Charles Greg	Officer	Mar 11 '26	Proposed Sale	60.46	16,486	996,749		Mar 11 03:23 PM
Friberg Gregory R	EVP, Chief R&D Officer	Feb 26 '26	Sale	60.38	6,326	381,937	37,578	Feb 26 08:39 PM
Davis George Eric	EVP, Chief Legal Officer	Feb 26 '26	Sale	61.36	26,061	1,599,103	72,453	Feb 26 08:31 PM
Friberg Gregory R	Officer	Feb 26 '26	Proposed Sale	60.38	6,326	381,937		Feb 26 01:59 PM
Davis George Eric	Officer	Feb 26 '26	Proposed Sale	61.36	26,061	1,599,103		Feb 26 10:18 AM

$100 Off Your First Year Get Elite For Just $199.50

IMNM

Immunome Inc

BMRN

Biomarin Pharmaceutical Inc

Upgrade your Finviz experience